NXC-201, a pioneering CAR-T therapy for multiple myeloma and AL amyloidosis, will have its latest clinical data unveiled at the upcoming Rotterdam event on February 9-11, 2023. Be among the first to learn about the groundbreaking advancements in the field of cancer treatments!
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX), is thrilled to announce that the latest clinical data for NXC-201 will be showcased at the upcoming European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting in Rotterdam, Netherlands from February 9-11, 2023. This is a great opportunity to showcase the therapeutic potential of NXC-201 and ImmixBio’s commitment to pioneering innovative treatments in the field of oncology.
We are thrilled to be showcasing more clinical data at the upcoming 5th Annual European CAR T-cell Meeting hosted by the European Society for Blood and Marrow Transplantation and the European Hematology Association. Our research is uncovering the potential of this promising therapy in treating multiple myeloma and AL amyloidosis, and we look forward to furthering our understanding of its efficacy through the data gathered in this study. Dr. Polina Stepensky, Director of the Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Immunotherapy for Adults and Children, is the principal study investigator.
Posters to be presented:
Hadassah Medical Center has gained extensive experience in the point-of-care manufacture and delivery of chimeric antigen receptor (CART) therapy for the treatment of multiple myeloma and AL amyloidosis. By providing this cutting-edge therapy at the patient’s bedside, Hadassah is revolutionizing the treatment of these serious conditions.
NXC-201, previously known as HBI0101, is showing remarkable success in treating multiple myeloma and AL Amyloidosis. In a clinical trial, 85% of patients with multiple myeloma achieved an overall response rate, with 71% achieving a complete response or stringent complete response. Even more impressively, the 4 patients with AL Amyloidosis achieved a 100% response rate and organ response rate. What’s more, no neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANs) were observed with NXC-201 treatment, as confirmed by the Haematologica and Clinical Cancer Research publications.
NXC-201 may become the first and only out-patient CAR-T treatment for Multiple Myeloma, AL Amyloidosis, and other BCMA-positive malignancies, with a low-grade (grade 1/2) CRS duration of just two days, beginning one day after dosing, and lasting up to five days, at a therapeutic dose for those in the relapsed/refractory stage of the disease. This could be a major breakthrough for those fighting these life-threatening illnesses.
NXC-201 (formerly HBI0101) is being evaluated under NEXICART-1 (NCT04720313), an open-label Phase 1b/2 study that is currently enrolling adults with relapsed or refractory multiple myeloma who are triple-class refractory (to at least 1 immunomodulatory drug, 1 proteasome inhibitor and 1 anti-CD38 antibody) by June 27, 2022. This exciting trial aims to assess the safety and efficacy of this novel treatment.
The Phase 1b portion of the study seeks to identify the Maximally Tolerated Dose (MTD) of NXC-201 and establish the safety of the treatment. Once the MTD has been determined, the Phase 2 portion of the study will focus on evaluating the efficacy of NXC-201 in terms of overall survival, progression-free survival and response rates, according to the International Myeloma Working Group (IMWG) Uniform Response Criteria.
NXC-201 is an exciting new investigational chimeric antigen receptor T (CAR-T) cell therapy that is being developed with the goal of providing relief to patients suffering from relapsed or refractory multiple myeloma and amyloidosis. This revolutionary therapy employs a proprietary BCMA-targeting CAR structure, which has already demonstrated reduced toxicity in the NEXICART-1 trial, making it a candidate for outpatient treatment. We are confident that this innovative approach will provide a much-needed breakthrough in the fight against these potentially deadly diseases.
About Multiple Myeloma
Every year, 34,470 Americans face the devastating diagnosis of multiple myeloma (MM), an incurable blood cancer of plasma cells. Unfortunately, the prognosis for those who don’t respond to or relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, is poor. Yet the fight against MM continues, as researchers seek new treatments to help those affected achieve a remission and, potentially, a cure.
About Nexcella, Inc.
Nexcella, Inc., a subsidiary of Immix Biopharma, Inc (NASDAQ:IMMX), is revolutionizing the field of biopharmaceuticals with its cutting-edge N-GENIUS cell therapy platform. Our platform enables us to discover, develop, and manufacture the most innovative cell therapies available for treating oncology and other indications. We are committed to improving the lives of patients in need and are dedicated to providing the highest quality treatments.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio™) (Nasdaq: IMMX) is a revolutionary biopharmaceutical company that is pushing boundaries in the field of oncology and immuno-dysregulated diseases. Our proprietary SMARxT Tissue-Specific™ Platform is leading the way in creating drug candidates that target not only the tumor, but also the metabolic and structural support that sustains it. Our TME Normalization™ technology is revolutionizing the way we treat cancer, and has the potential to sever the lifelines between the tumor and its support, providing long-term relief for patients.
Forward Looking Statements
At Immix Biopharma, Inc., we believe that the future holds immense promise and potential. That’s why we’re committed to developing and commercializing products and services that can benefit the lives of people everywhere. However, there are numerous risks and uncertainties that could prevent us from achieving our desired outcomes, such as our ability to raise capital to fund continuing operations; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; and changes in government regulation. Our Annual Report on Form 10-K for the year ended December 31, 2021, provides a more comprehensive overview of these risk factors. We are hopeful that our efforts will allow us to realize our vision and create a brighter future for all.
At any time, unforeseen factors or events may arise and lead to unexpected results. We cannot anticipate everything that may come our way, and as such, we cannot guarantee future performance and achievements. However, we are committed to doing our best to ensure that we reach our goals and objectives.